Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Rhea-AI Summary
Helus Pharma (Nasdaq: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), will participate in the Jefferies Global Healthcare Conference in New York from June 2-4, 2026.
Interim CEO Eric So will join a webcast fireside chat on Thursday, June 4, 2026, at 2:35 p.m. EDT, with a replay available on the company’s investor relations site.
Positive
- None.
Negative
- None.
News Market Reaction – HELP
In the Jun 1 session, HELP gained 3.08%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Veteran outreach partnership | Positive | -3.0% | Collaboration with TARA Mind to support PARADIGM HLP003 Phase 3 recruitment. |
| Apr 30 | Conference participation | Positive | +8.2% | CEO panel at Milken Global Conference with webcast access for investors. |
| Apr 28 | Partnership announcement | Positive | -4.4% | Partnership with TARA Mind and VETS to expand veteran mental health outreach. |
| Apr 23 | Advisory board additions | Positive | -0.3% | Appointment of Dr. Robert Langer and Dr. Stephen Brannan to advisory board. |
| Apr 20 | Policy support statement | Positive | +2.0% | Company support for Executive Order advancing psychedelic research pathways. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates often saw mixed or negative next-day reactions, with conference participation sometimes drawing stronger interest than clinical or partnership news.
Over the last six weeks, HELP has issued multiple updates tied to its late-stage pipeline and strategic positioning. Partnership announcements around the PARADIGM HLP003 Phase 3 program and veteran mental health outreach saw next-day moves of -3.01% and -4.44%, while reinforcing its FDA Breakthrough Therapy status. Management and advisory board strengthening on April 23, 2026 had little price impact. In contrast, general visibility events like the Milken conference on April 30, 2026 coincided with an 8.15% gain, suggesting investor attention can concentrate around high-profile appearances similar to the Jefferies conference.
Key Terms
serotonergic agonists medical
clinical-stage medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT
NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Eric So, Helus Pharma’s Interim Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, taking place June 2-4, 2026.
The fireside chat will be webcast live on Thursday, June 4, 2026, at 2:35 p.m. EDT.
To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma’s investor relations website.
About Helus Pharma
Helus Pharma™, the commercial operating name of Cybin Inc. (the “Company” or “Helus Pharma”) is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs - novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Cybin Corp.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2025, and the Company’s annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com
George Tziras
Chief Business Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com
Media Contact:
Johnny Tokarczyk
RXMD
Public Relations Director
jtokarczyk@rxmedyn.com
(914) 772-7562
